Study in mice found transient microglial depletion, or chemokine receptor blockade, resolved immunotherapy-related cognitive impairment.

Integra Therapeutics, a global leader in creating cutting-edge gene-writing tools to improve the efficacy, precision and ...

UK-based Leucid Bio has dosed the first subject in the multi-centre Phase I AERIAL trial of autologous lateral chimeric ...

Second of 2 parts featuring an interview with Stephen Strickland, MD, MSCI,director, Leukemia Research for Sarah Cannon ...

Data for SKYSCRAPER-01, involving the anti-TIGIT antibody tiragolumab, seem to align with recent bad news for this ...

Q1 2025 Earnings Call Transcript May 12, 2025 Coherus BioSciences, Inc. misses on earnings expectations. Reported EPS is ...

Chimeric Antigen Receptor T-cell (CAR-T) therapy has revolutionised cancer treatment, especially for aggressive and ...

Initiation of AERIAL trial accelerated by successful first close of Series A1 financing  LEU011 is first CAR-T candidate for the treatment of solid tumours to be manufactured ...

Our trial provides proof of concept that cytokine-armored CAR T-cell treatment is feasible and may enhance antitumor activity without additional toxic effects,” researchers reported.

After treatment with CAR-T cells - immune cells engineered to attack cancer - patients sometimes tell their doctors they feel like they have "brain fog," or forgetfulness and difficulty concentrating.